Core Insights - Senseonics Holdings, Inc. (SENS) has achieved a significant commercialization milestone with the launch of the Eversense 365 continuous glucose monitor (CGM) integrated with the twiist automated insulin delivery (AID) system, marking the first pairing of a one-year, implantable CGM with an AID platform [2][3][7] Company Developments - The integration with Sequel MedTech enhances diabetes management by reducing sensor changes and enabling automated insulin adjustments, with broader availability expected by March 2026 [3][10] - The Eversense 365's implantable design allows for uninterrupted glucose monitoring for up to one year, addressing common issues associated with frequent sensor changes [9] - SENS reported a strong improvement in its third-quarter 2025 financial performance, with total revenue rising to $8.1 million from $4.3 million year-over-year, driven by a 160% increase in new patient growth in the U.S. [12] - The company achieved a gross profit of $3.5 million in the quarter, a significant improvement from a gross loss of $4.1 million a year ago, indicating progress in cost structure and operating efficiency [14] Market Position and Trends - Following the announcement of the Eversense 365 launch, SENS shares gained 8%, although they have declined 28.8% over the past six months compared to a 10.5% decline in the industry [4] - The global blood glucose monitoring devices market is projected to grow from $15.53 billion in 2025 to $30.18 billion by 2033, expanding at a CAGR of 8.8% from 2026 to 2033, driven by the increasing prevalence of diabetes [11]

As filed with the Securities and Exchange Commission on December 19, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MiniMed Group, Inc. (Exact name of registrant as specified in its charter) (Primary Standard Industrial Classification Code Number) Delaware 3841 33-3985981 (I.R.S. Employer Identification Number) 18000 Devonshire St. Northridge, CA 91325 (763) 514-4000 (Address, including zip ...

Core Insights - Tandem Diabetes Care, Inc. (TNDM) is experiencing significant international expansion, which is expected to enhance growth in upcoming quarters. The company's strategic initiatives present favorable growth opportunities, although there are concerns regarding its heavy reliance on insulin pumps and the impact of macroeconomic challenges [1][9]. Financial Performance - Over the past year, TNDM's shares have declined by 38.7%, while the industry saw a minor decline of 0.3%. In contrast, the S&P 500 composite has increased by 16.4% during the same period. The company has a market capitalization of $1.15 billion and projects a growth rate of 59.2% for 2026 earnings, compared to 14.7% for the S&P 500 [2]. Strategic Developments - Tandem Diabetes is focusing on growth through acquisitions and investments in new technologies. The company has a competitive edge due to its rapid integration of Continuous Glucose Monitoring (CGM) systems, supported by partnerships with Dexcom and Abbott. The t:slim X2 pump is now compatible with Eli Lilly's ultra-rapid-acting insulin, Lyumjev [3][5]. - Operational improvements are being implemented to enhance efficiency, including streamlining processes and increasing automation. In Q3, Tandem achieved significant milestones by expanding pharmacy benefit coverage for Tandem Mobi to over 40% of U.S. covered lives and began selling t:slim supplies through pharmacy benefits [4]. International Market Focus - The International Diabetes Federation projects that by 2030, around 643 million people globally will have diabetes. Tandem's international expansion strategy aligns with this trend, allowing the company to capitalize on substantial market opportunities. In Q3, revenues outside the U.S. increased by 1.8% year-over-year, with approximately 9,000 pumps shipped across 25 markets [5][6][8]. Challenges - Macroeconomic uncertainties pose challenges for TNDM, making it difficult to predict product demand accurately. These conditions could lead to increased expenses and negatively affect financial performance. In Q3, the company reported a net loss of $21.2 million [9]. - TNDM's heavy dependence on insulin pumps is a concern, as these products accounted for 44.2% of worldwide sales in Q3 2025. Factors affecting market acceptance among insulin-dependent diabetes patients and healthcare providers could hinder the company's business and financial results [10]. Revenue Estimates - The Zacks Consensus Estimate for TNDM's 2025 loss per share has narrowed by 5 cents to $2.35 over the past 30 days. Revenue estimates for 2025 are projected at $1.00 billion, indicating a 9.9% increase from the previous year [11].

Core Insights - Insulet Corporation hosted its 2025 Investor Day, outlining a strategic plan to maintain leadership in the automated insulin delivery market for diabetes management [1][2][3] Strategic Plan and Market Focus - The company aims to drive growth in a total addressable market exceeding $30 billion by enhancing innovation, improving clinical practices, expanding access, and achieving commercial excellence [2][5] - Insulet's competitive advantages include its unique product design, a pay-as-you-go pharmacy model, advanced manufacturing capabilities, and a strong financial position [2][5] Financial Outlook (2025-2028) - Revenue is projected to grow at a compound annual growth rate (CAGR) of approximately 20% at constant currency rates, driven by increased adoption of Omnipod products and geographic expansion [7] - Adjusted operating margin is expected to expand by about 100 basis points annually, reflecting operational efficiencies [7] - Adjusted diluted earnings per share are anticipated to grow at a CAGR of over 25%, indicating a commitment to profitable growth [7] - Free cash flow is forecasted to remain strong, allowing for disciplined reinvestment in innovation and global scaling [7] Innovation Pipeline - Insulet introduced enhancements to the Omnipod 5, set to launch in 2026, along with two next-generation systems aimed at expanding market reach and improving automated insulin delivery [5][11] - The Omnipod 6, expected in 2027, will feature an adaptive algorithm for better glucose control and enhanced connectivity [11] - The Omnipod Fully Closed Loop for Type 2, planned for 2028, will be the first fully automated system designed specifically for type 2 diabetes, simplifying insulin delivery [11]

Company Overview - Insulet's 2024 revenue reached $2.1 billion[21] - The company has over 500,000 active Podders globally[21] - Approximately 365,000 users are utilizing Omnipod 5[21] Financial Performance and Growth - The company is growing revenue beyond $2.5 billion[25] - The company anticipates approximately 24% compound annual growth rate (CAGR)[25] - The company is experiencing greater than 660 basis points (bps) expansion in leading gross margin[25] - The company is experiencing approximately 1,010 bps expansion in adjusted operating margin[25] Omnipod 5 Impact and Market - Omnipod 5 demonstrated a 20%-23% increase in time in range for adults with Type 1 and Type 2 diabetes, respectively[28] - The company estimates a total addressable market of approximately 14 million patients[41] - U S Type 1 Diabetes market penetration is approximately 40%[40]

Core Insights - Insulet (PODD) has experienced a significant share price increase of 37.4% over the past year, outperforming the industry decline of 0.5% and the S&P 500's gain of 17.5% [1][8] - The company is enhancing its leadership in the diabetes market through the Omnipod 5, which is driving strong adoption and market growth [1][3] Company Overview - Insulet, based in Acton, MA, specializes in manufacturing and selling continuous insulin delivery systems for insulin-dependent diabetes [2] - The Omnipod platform offers a unique, tubeless insulin delivery system and is available in 25 countries [2] Growth Drivers - The share price rally is attributed to the strong momentum of Omnipod 5, the only FDA-cleared, fully disposable pod-based automated insulin delivery system [3] - Key product features such as on-body wearability and ease of use are contributing to rapid adoption [3] - Recent milestones include the U.S. launch of the Omnipod 5 App integrated with Dexcom G7 CGM system [3][4] Market Expansion - Omnipod DASH is gaining traction in the U.S. type 2 diabetes market, accounting for approximately 30% of new starts [4] - Insulet has received FDA clearance for type 2 label expansion for Omnipod 5, further enhancing its market position [4] - The company is expanding its market presence in Europe and has launched Omnipod Discover, a digital platform for personalized data management [5] Market Potential - The diabetes market remains underpenetrated, with only about 40% of the Type 1 diabetes population in the U.S. using insulin pump therapy [6] - Insulet is focusing on commercial expansion and market access, including salesforce growth and targeted pediatric center entry [9] Financial Estimates - The Zacks Consensus Estimate projects Insulet's earnings per share (EPS) to increase by 42.9% in 2025 and 24.3% in 2026, reaching $4.63 and $5.76 respectively [11] - Revenues are expected to grow by 26.4% in 2025 to $2.62 billion and by 18.1% in 2026 to $3.09 billion [11]

Company Overview and Market Position - Insulet is a global leader in diabetes management with $2.1 billion in 2024 revenue[21] - The company has approximately 500,000 active customers globally[21] - Omnipod is the 1 AID system requested and prescribed in the U S [21] - Omnipod 5 is the first AID system FDA-cleared for both type 1 and type 2 diabetes in the U S [21] Financial Performance and Growth - The company is growing revenue beyond $2.5 billion[24] - The company anticipates approximately 24%-27% constant currency revenue growth for full year 2025[25] - The company is experiencing rapid expansion of adjusted operating margin, with an anticipated expansion of approximately 1,000 bps to reach 17%-17 5%[24, 25] Product Innovation and Clinical Outcomes - Omnipod 5 is the first and only tubeless, waterproof AID in the U S [27] - Omnipod 5 leads to a 20%-23% increase in time in range for adults with type 1 and type 2 diabetes, respectively[27] - Strong SECURE-T2D clinical results show a 0 8% reduction in mean A1c in 13 weeks[29] Market Opportunity and Expansion - The total addressable market is approximately 14 million patients[40] - The company is expanding its market presence outside the U S [50] - The company is building the power of its Omnipod 5 brand globally[57]

Core Insights - Medtronic plc has received CE Mark approval in Europe to expand the indications for the MiniMed™ 780G system, allowing its use for individuals aged 2 years and older, during pregnancy, and for those with type 2 diabetes [1] Group 1: Expanded Indications - The MiniMed™ 780G system is now indicated for children aged 2-6 years with type 1 diabetes, showing a 0.6% reduction in HbA1C and a 9.9% increase in time in range when used in auto mode compared to manual mode [2] - The system has been recognized as a standard of care for children with type 1 diabetes across Europe, with guidelines from NICE and the German Diabetes Association recommending its use [3][4] Group 2: Pregnancy Management - The MiniMed™ 780G system offers significant benefits for managing type 1 diabetes during pregnancy, achieving an average Pregnancy Time in Range (TIRp) of 66.5%, which is an improvement over traditional insulin therapy [6] - Clinical guidelines emphasize the importance of tighter glucose control during pregnancy, with the MiniMed™ 780G system providing better overnight glucose control and higher treatment satisfaction among expectant mothers [5][6] Group 3: Type 2 Diabetes Indication - The MiniMed™ 780G system is now also approved for individuals with type 2 diabetes, demonstrating a 0.7% reduction in HbA1c and an increase in time in range to 80% in a pivotal trial [7] - Real-world data from 26,427 users with type 2 diabetes showed good glycemic control, exceeding the international consensus of 70% time in range [7] Group 4: Future Developments - Medtronic is working with U.S. regulatory authorities to expand the use of the MiniMed™ 780G system for individuals with type 2 diabetes, with ongoing clinical trials for children aged 2-6 years [8]

Financial Performance & Growth - Insulet achieved market-leading revenue growth and value creation[11] - The company is driving financial results through strong execution and margin expansion[7, 55] - In 2023, Insulet marked its 8th consecutive year of total company revenue growth of 20% or more[18] - Q3 2024 saw a gross margin of 693%, a +150 bps increase, and an operating margin of 162%, a +350 bps increase[18] - Q3 2024 U S revenue growth was 23%, total Omnipod revenue growth was 26%, and international revenue growth was 35%[18] - The company's revenue has grown from $07 billion in 2019 to $21 billion in 2024E, with a 23% CAGR[15] Omnipod 5 Platform & Clinical Outcomes - Omnipod 5 simplifies diabetes management and is winning on all dimensions[28, 31] - Omnipod 5 demonstrated a 175%-20% increase in time in range in adults with T1D and T2D, respectively[32] - Real-world results in 70000 Omnipod 5 users showed adults (18+ yrs) achieved 688% time in range and pediatrics (2-17 yrs) achieved 644% time in range[36, 37] - The SECURE-T2D trial demonstrated a 08% reduction in A1C with Omnipod 5 in T2D patients[39] Market Opportunity & Sustainability - Insulet is well-positioned for large market opportunities, with ~14M TAM across markets in different stages of pump penetration[23] - The company is focused on healthcare providers and direct-to-consumer initiatives to drive awareness[47] - Insulet is committed to sustainability, with initiatives including increased renewable energy generation (802kW potential) and a 77% reduced carbon footprint in redesigned U S Omnipod 5 starter kit packaging[48, 49]

Company Overview - Tandem Diabetes Care, Inc. (TNDM) has launched its t:slim X2 insulin pump with Control-IQ+ technology, now compatible with Abbott's FreeStyle Libre 3 Plus continuous glucose monitoring sensor in the U.S. An early access program has been initiated, with plans for broader availability in the second half of 2025 [1][9]. Stock Performance - Following the announcement of the new compatibility, TNDM's shares increased by 1.6%, reaching $20.55 [2]. However, over the past year, TNDM shares have experienced a decline of 49.4%, compared to a 14.8% decline in the industry [12]. Financial Metrics - Tandem Diabetes has a market capitalization of $1.35 billion and is projected to have an earnings per share (EPS) growth rate of 28.3% in 2025, significantly higher than the industry's expected growth of 13.8%. Revenue for 2025 is anticipated to rise by 10.6% [4]. Product Features - The t:slim X2 insulin pump utilizes advanced hybrid closed-loop technology, adjusting insulin delivery every five minutes based on predicted glucose values. It features the unique AutoBolus function, which calculates and delivers correction boluses for missed meals [5]. The FreeStyle Libre 3 Plus sensor offers a 15-day wear time and transmits glucose readings every minute to the t:slim mobile app [6]. Industry Insights - The global insulin delivery device market was valued at $16.43 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 7.9% by 2027, driven by the increasing prevalence of diabetes and advancements in technology [7][10]. Strategic Developments - Tandem Diabetes has entered an agreement to develop integrated diabetes solutions that will combine Abbott's future dual glucose-ketone sensor with Tandem's insulin delivery systems, enhancing options for diabetes management [11].